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ABSTRACT: The aim of the study was to determine whether zileuton, an inhibitor 
of 5-lipoxygenase, attenuated bronchial hyperresponsiveness (BHR) in asthmatic 
subjects who had marked BHR during maintenance treatment with inhaled cor­
ticosteroids (ICS).
In a randomized, double-blind, placebo-controlled, cross-over study, a challenge 
test with histamine (provocative concentration of histamine producing a 20% fall 
in forced expiratory volume in one second (FEVi) (PC 2 0 ,riist)) and with ultrason- 
ically nebulized distilled water (UNDW) (provocative dose of UNDW producing a 
20% fall in FEVi (PD20,undw)) was performed in seven patients with asthma after 
intake of either 400 mg zileuton or placebo. All patients (mean age 33 yrs, mean 
FEVi 111% of predicted) had marked BHR, as indicated by a mean PDzo,undw 
of 4,74 mL under treatment for at least 6 months with up to 800 ICS (mean 
536 {ag daily). On four different occasions, separated by at least 5 days, two UNDW 
and two histamine challenge tests were performed in random order 3 h after a 
morning dose of either zileuton or placebo.
Neither zileuton nor placebo changed baseline airway calibre prior to provoca­
tion. Zileuton increased PC2 0 ,Hist from 0.99 to 5.64 in g m L 1 (2.1 doubling doses; 
p<0.03 compared to placebo), and increased PD20,undw from 3,10 to 9.31 mL (1.3 
doubling doses; pcO.05 compared to placebo).
In conclusion, a single dose of 400 nig zileuton attenuates bronchial hyperre­
sponsiveness to histamine and ultrasonically nebulized distilled water in asthmatic 
patients with marked bronchial hyperresponsiveness during treatment with 
inhaled corticosteroids.
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Current therapy for asthma is aimed at suppressing 
the inflammatory process in the wall of the airways, 
thus reducing symptoms of bronchial hyperresponsive­
ness (BHR) and airways obstruction. Inhaled corticos­
teroids (ICS) have been shown to be very effective in 
this respect. This may result in a tendency towards pre­
scribing high doses for prolonged periods of time. In this 
respect, concerns about the safety of ICS have recently 
been addressed [1» 2]. ICS may reduce serum cortisol 
levels, alter biochemical markers of bone metabolism, 
and, in children, suppress growth velocity. The long­
term clinical significance o f these changes is not yet 
clear.
Other classes of anti-inflammatory agents for the treat­
ment of asthma are currently under investigation. One 
of these drugs, zileuton (AM~(benzo(/?)thien-2-ylethyl)- 
N-hydroxyurea), an inhibitor of the 5-lipoxygenase 
pathway, has been shown to be efficacious in patients 
with asthma [3-6]. Single-dose studies have shown an 
attenuation of the asthmatic response to cold dry air [7], 
but not after allergen challenge [8], In aspirin-sensitive
For editorial comment see page 2701
asthmatics, 2.4 mg zileuton daily for 1 week prevented 
the fall in forced expiratory volume in one second (FEV i) 
in response to ingestion of aspirin [9]. A similar dose, 
administered for 2 days, attenuated exercise-induced 
bronchoconstriction [10], A 13 week treatment period 
with zileuton, 1.6 or 2.4 mg daily, resulted in a 58% 
increase in the cold air minute ventilation required to 
cause a 15% decrease in FEVi [11]. Asthma symptoms 
and FEVi improved after 4 [12] to 13 weeks [13] of 
treatment with a similar dose of zileuton, without clear
side-effects [12],
Whether zileuton has an additional effect on BHR in 
patients already treated with ICS is unknown. Such an 
action would be of potential clinical relevance, since it 
would allow tapering of the dosage of ICS. In the pre­
sent study, this question was addressed by measuring the 
effect of a single dose of 400 mg zileuton during chal­
lenge with histamine (which, in the main, acts directly 
on airway smooth muscle) and ultrason ically-nebulized 
distilled water (UNDW) (which induces bronchocon­
striction by the release of several mediators) in patients 
with asthma who were on maintenance treatment with
ICS.
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Patients and methods
Study design
This study was carried out using a randomized, dou­
ble-blind, placebo-controlled, cross-over design. Seven 
patients with asthma according to the American Thor­
acic Society (ATS) criteria [14], who had marked BHR 
during treatment for at least 6 months with up to 800 
jxg ICS, were studied. They were tested on four different 
occasions separated by at least 5 days within a period 
of 4 weeks. Two challenge tests with UNDW (provo­
cative dose of UNDW causing a 20% fall in FEVi) 
(PD20,UNDW)) and two with histamine (provocative 
concentration of histamine causing a 20% fall in FEVi 
(PC20,Hist)) were performed in random order 3 h after 
an 09:00 h dose of either zileuton or placebo.
Subjects
Nonsmoking patients with allergic asthma, who 
exhibited marked BHR under maintenance treatment 
with ICS for at least 6 months, were selected. Allergy 
was defined as an elevated specific immunoglobulin E 
(IgE) or a positive skin-prick test for house dust mite 
or at least two other common aeroallergens [15] Pa­
tients were included if their FEV l was above 70% of pred­
icted [16] and PD20JJNDW was below 8 mL. The second 
criterion was set for two reasons: firstly, from previous 
studies in our laboratory it appeared that this level of 
PD20.UNDW was associated with a PC20,Hist of less than 
4 mg-mL'1 [17, 18]; and, secondly, these levels of BHR 
provide the opportunity for measurable improvement 
by the drug under investigation. The current use of ICS 
(beclomethasone dipropionate or budesonide, either 
by metered-dose inhaler (MDI) or by dry powder) was 
not allowed to be higher than 800 \ig daily. All sub­
jects used salbutamol as rescue medication. Patients on 
long-acting ß2-agonists, theophylline and oral anticoag­
ulative drugs, as well as patients who were pregnant or 
breast-feeding, were excluded from participation in the 
study.
A total number of 17 patients, fulfiling the require- 
ments with regard to current medication, were screened 
to participate. Ten subjects were not enrolled into the 
study, since the screening UNDW challenge test appeared 
to be negative. By chance, the seven subjects partici­
pating in the study were all female. Laboratory testing 
(complete blood count, serum chemistry) was performed 
after each provocation to assess the safety and toler- 
ability of zileuton.
Measurement o f  lung function and BHR
Subjects did not use ICS or rescue medication for at 
least 8 h before each visit and rested 30 min before the 
measurements were started. Baseline FEVi on the four 
study days had to be within 10%, otherwise the test was 
postponed to a later day. Lung function and responses 
to provocation with histam ine and U N D W  were 
assessed by FEV l , measured with a flow-volume curve 
recorded on a heated pneumotachograph (Spiro analyzer
ST 250®; Fukuda Sangyo Co., Tokyo, Japan). Baseline 
lung function was recorded as the best of three repro­
ducible values of FEVi (within 5%) before the provo­
cation tests.
The same technician from the lung function depart­
ment always checked the patients morning FEV 1. If the 
patient fulfilled the entry criteria, the technician then 
delivered the correct tablet according to the random­
ization list. Randomization was performed in blocks of 
four prior to the start of the study. For each participant 
number a sequence of measurements with either tablet 
"A” of "B" was listed according to the randomization 
list.Thefour tests (i.e. A-Hist, A-UNDW, B-Hist,B-UNDW)
were sequenced at random. The patients received oral 
zileuton (capsules, 400 mg) or placebo capsules of 
identical appearance (both supplied by Abbott Labora­
tories) according to a blinded and randomized code. 
This dose of zileuton was chosen since leukotriene B4 
(LTB4) production by ex vivo calcium ionophone-stim- 
ulated whole blood from healthy volunteers was inhib­
ited by up to 80% of baseline. This response was studied 
in dosages of 200, 400, 600 and 800 mg of zileuton, 
and this reduction appeared to plateau at a dose of 400 
mg [19]. Thus, 400 mg appeal's to be a dose that might be 
expected to have some physiological effect,
Three hours after intake, FEVi was measured again. 
Subsequently, the provocation tests were performed. 
The histamine provocation test was carried out accord­
ing to the method of C ockcroft  et al. [20]. For 2 min, 
patients inhaled doubling concentrations of histamine 
acid phosphate by tidal breathing, increasing from 
0.03 to 16 mg-mL-1. Histamine was nebulized with a 
DeVilbiss 646 nebulizer (DeVilbiss, Somerset, PA, USA) 
with a fixed output of 0.13 mg-mL-1. PC20,Hist was 
determined in mg-mL-1 by interpolating the last two 
points of the dose-response curve on a semilogarithmic 
scale. Responsiveness to UNDW was assessed according 
to the method of G root et aL [17]. UNDW was gen­
erated with an ultrasonic nebulizer (Ultraneb 99; DeVilbiss, 
Somerset, PA, USA) at a fixed output of 2.00+0.05 
mg'mL'1. After inhalation of 20 L of ambient air 
through the system, patients inhaled doubling volumes 
of air with UNDW (3, 5, 10, up to 160 L), measured 
with a Wright respirometer (British Oxygen Co., London, 
UK). The respirometer was placed between the aerosol 
hose and the mouthpiece by means of a two-way valve. 
Before and after each test, the nebulizer chamber and 
aerosol hose were weighed to determine the exact amount 
of distilled water inhaled. The cumulative amount of 
inhaled water (mL) causing a 20% fall in FEVi from 
post-air values (PD20,UNDW) was calculated by linear 
interpolation on a semilogarithmic curve.
Statistical analysis
PC20 and PD20 values were log transformed before 
analysis and compared by analysis of variance using the 
Statistical Package for the Social Sciences (SPSS) ver­
sion 5.0 software [21]. Paired data were analysed using 
the Wilcox on signed rank test. Carry-over effects were 
analysed according to Pocock [22] using the Man 11- 
Whitney U-test. Results are presented as means and 
standard errors of the means (se m ). Significance was 
accepted at a p-value of less than 0.05.
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Results
Patient characteristics are summarized in table 1. 
Their baseline FEVi ranged 86-134% pred. The daily 
use of ICS ranged 200-800 \xg daily (mean 536 jig). 
Under this medication all patients had marked BHR, as 
indicated by a mean PD20,undw of 4.74 mL at entry
Table 1. -  Patients characteristics at baseline
32.0 -
Pt Age ICS ß2 use Prestudy PD20.UNDW
No. FEVi
yrs m g-day1 mg*day-' L % pred mL
1 19 BDP, 400 0.1 p.r.n. 3.53 115 3.01
2 57 BDP, 750 0 4  p.r.n. 2.70 134 7.98
3 36 BUD, 800 0.8 2.41 86 3.61
4 20 BDP, 200 0.4 p.r.n. 3.17 88 3.97
5 27 BUD, 400 0.8 4.01 119 5.48
6 27 BDP, 400 0.1 p.r.n. 3 4 2 111 3.18
7 44 BDP, 800 1.6 3.00 125 6,00
Mean 33 536 3.18 111 4.74
SEM 5 92 0.20 7 0.69
Pt: patient; ICS: inhaled corticosteroids; ß2 use: mean daily 
use of ß2-agonist in the previous 6 months; FEVi: forced expi­
ratory volume in one second; PD2 0 ,undw: provocative dose 
of ultrasonica! I y nebulized distilled water causing a 20% fall 
in FEVi from baseline; BDP: beclomethasone dipropionate; 
BUD: budesonide.
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Fig. 1. -  Individual data for the provocative concentration of hist­
amine causing a 20% fall in forced expiratory volume in one second 
(PC20.Hist) after placebo (open symbols) and zileuton (closed sym­
bols). Values are presented as mean±sEM, increasing from 0.99 (0.29) 
after placebo to 5.64 (2.27) mg-mL'1 after zileuton (2.1 doubling 
doses; p<0.03). The same symbols for individual patients are used in 
figures 1 and 2.
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Fig. 2. -  Individual data for the provocative dose of ultrasoni- 
cally nebulized distilled water causing a 20% fall in forced exp i­
ratory volum e in one second (PD20.UNDW) after placebo (open 
symbols) and zileuton (closed symbols). Values are p resen ted  as 
mean±sEM, increasing from 3.10 (0.56) after placebo to 9.31 (3.38) 
mL after zileuton (1.3 doubling doses; p<0.05). The same sym ­
bols for individual patients are used in figures I and 2.
into the study and a mean PC20,Hist of 0.99 mg-mL’1 
after placebo (fig, 1). Zileuton was well tolerated. No 
haematological or biochemical changes were observed 
after treatment,
Baseline FEVi before administration of zileuton or 
placebo was similar on the four occasions (table 2). 
Neither zileuton nor placebo changed FEVi 3 h after 
intake. Thus, zileuton did not cause acute bronchodila- 
tion in these patients.
Zileuton increased PC20,Hist from 0.99 (0.29) to 5.64 
(2,27) mgTnL-1 (2.1 doubling doses (DD); p<0.03 com­
pared to placebo) (fig, 1), In six of the seven patients, 
a clear increase was observed. PD20,UNDW was increased
from 3,10 (0.56) to 9.31 (3.38) mL (1.3 DD; p<0.05
compared to placebo) (fig, 2), Again, an improvement 
was observed in all but one patient (which was not the 
same patient as the one that showed no improvement of 
the PC20,Hist).
To exclude some unexpected order effect, table 3 lists 
the individual data set out by order of challenge and 
drug with the gap between the challenges applied. 
Apparently, no order effect was present; e.g. patients 
who received zileuton at the last challenge (Nos, 1, 3,  
6 and 7) and patients who received placebo at the last 
challenge (Nos. 2, 4 and 5) both showed improvements 
in the level of hyperresponsiveness.
Table 2. -  FEVi at baseline and at the start of each provocation test
Pt Zileuton Placebo
No. FEVi before histamine FEVi before UNDW FEV l before histamine FEVi before UNDW
Baseline After 3 h Baseline After 3 h Baseline After 3 h Baseline After 3 h
L L L L L L L L
1 3.58 3.53 3.76 3.54 3.68 3.52 3.78 3.59
2 2.65 2.71 3.04 2.98 2.73 2,40 2.80 2.83
3 2.42 2.35 2.50 2.39 2.32 2.30 2,31 2.47
4 3.22 3.30 3.12 3.32 3.19 3.24 3.13 3.05
5 4.03 4.01 3.79 3.67 4.04 3.69 3.99 3.56
6 3.51 3.71 3.75 3.86 3.57 3.77 3.71 3.76
7 3.03 3.13 3.14 3.36 3.15 3.29 3.17 3.11
Mean 3.21 3.25 3.30 3.30 3.24 3.17 3.27 3.20
SEM 0.21 0.22 0.19 0.19 0.22 0.22 0.23 0.17O C 1 V 1  V  * i  V
FEV 1 : forced expiratory volume i water.
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Table 3. FEVi at baseline and at the start of each provocation test in the sequence of the tests performed
Pt
No.
2
3
4
5
6
7
Visit
FEVi
baseline 
and after 3 h 
L
1
Day 0 
3.58-^3,53 
Day 0 
2.80-^2.83 
Day 0 
2.31-»2,47 
Day 0 
3.19-^3,24 
Day 0 
4.03-^4,01 
Day 0 
3.71—>3,76 
Day 0 
3. J4—>3.36
Challenge
Visit 2
FEVi 
baseline 
and after 3 h 
L
Z-Hist
1.92
P-UNDW
2.32
P-UNDW
4.2
P-Hist
2.739
Z-Hist
>16
P-UNDW
2.35
Z-UNDW
>28.2
Day 7 
3.78—>3.59 
Day 6 
3 .0 4 ^ 2 ,9 8  
Day 7 
2.32—>2.30 
Day 6 
3 .1 2 -* 3 3 2  
Day 8 
3 ,7 9 ^ 3 .6 7  
Day 5 
3.57->3.77 
Day 7 
3 .1 7 ^ 3 .1 1
Challenge
P-UNDW
3.13
Z-UNDW
6.32
P-Hist
0.875
Z-UNDW
8.78
Z-UNDW
3.17
P-Hist
0,438
P-UNDW
5.6
Visit 3 
FEVi Challenge
baseline 
and after 3 h
L
Visit 4 
FEVi Challenge
baseline 
and after 3 h
L
Day 
3.68-h 
Day 
2 .6 5 -  
Day 
2.42 
Day
3 .22^
Day
4 ,0 4 -
Day 
3.75 
Day 
3 .1 5 -
14
3.52
13
2.7 i 
13
2.35
12
330
15
3.69
12
3.86
17
3.29
P-Hist
0.613
Z-Hist
1.348
Z-Hist
2.497
Z-Hist
2.806
P-Hist
0.676
Z-UNDW
2.20
P-Hist
0.983
Day 21
3.76-^3.54 
Day 20
2.73—>2.40 
Day 19
2.50-^2.39 
Day 19
3.13-^3.05 
Day 22
3.99->3.56 
Day 19
3.51—>3.71 
Day 23
3.13-^3.13
Z-UNDW
4.84
P-Hist
0.658
Z-UNDW
11.7
P-UNDW
3.20
P-UNDW
0.93
Z-Hist
2.273
Z-Hist
12.668
Z: zileuton; P: placebo. For further definitions see legend to table 2.
Discussion
The present study shows that a single dose of 400 mg 
zileuton improves BHR in asthmatic patients with marked 
BHR under maintenance treatment with ICS, Indeed, 
six out of seven patients showed an increase in PC20,Hist 
after zileuton in comparison to placebo, and, similarly, 
PD 20rU.NDW was improved in six of the seven patients. 
Neither zileuton nor placebo changed airway calibre, as 
indicated by no changes in FEVi during 3 h after intake.
To assess the efficacy of anti-inflammatory treatment, 
an indirect challenge (as with UNDW) may be of value 
since it mimics naturally occurring bronchoconstrictor 
stimuli and because it reflects the severity of asthma 
better than pharmacological stimuli [23, 24]. UNDW  
induces bronchoconstriction by cell-mediated events [24]. 
Challenge with UNDW may increase BHR and induce 
a late asthmatic response, just as occurs on exposure to 
allergens [25, 26]. The extent of the increase in PD20, 
UNDW ( 1.3 DD) in the present study was slightly less 
than in the study of G ro o t  et aL [27], who found an 
increase of 1.8 DD after 4 weeks of beclomethasone 
dipropionate, 800 pg daily. This may be explained by 
the fact that at baseline the present patients were less 
responsive to UNDW, the PD20,undw being 4.74 mL 
(at intake) and 3.1 mL (after placebo), compared to 1.3 
mL in the study by G root  et aL [27].
In contrast, inhaled histamine acts, in the main, directly 
on the airway smooth muscle [23]. The magnitude of 
increase in PC20,Hist after a single dose of 400 mg zileu­
ton (2.1 DD) resembles the effects of maintenance ther­
apy with ICS in previous studies. The average increase 
in PC20 ,Hist or methacholine after chronic treatment with 
beclomethasone dipropionate or budesonide, as recently 
reviewed by B arnes  and P edersen  [28], is about 1-2 DD.
To the best of our knowledge, no single- or multiple- 
dose studies have been performed looking directly at 
histamine or methacholine reactivity after the admin­
istration of 5-lipoxygenase inhibitors. With leukotriene 
receptor antagonists, a small but significant reduction 
(from 0,30 to 0.48 mg-mL“1) in methacholine respon­
siveness was observed after a 1 week treatment of asth­
matic patients with pranlukast [29], Therefore, the
magnitude of the acute effect of zileuton on histamine 
and UNDW reactivity observed in the present study is 
difficult to compare with previous data.
The mechanisms by which zileuton attenuates the 
response to histamine and UNDW in these asthmatics 
who are being treated with ICS are unknown. Previous 
studies showed that a single dose of 600 mg zileuton 
rapidly {i.e. within 1 h) increased FEVi by -0.35 L in 
patients with an FEVi of ~57-60% pred [12], Such 
improvement was not observed in other studies [7, 8] 
or in the present patients, presumably because the FEVi 
was close to its predicted value in these studies. Thus, 
an increase in airway calibre is unlikely to be the expla­
nation for the reduced responses to histamine and UNDW 
challenge after zileuton found in the present study.
Other mechanisms may be considered to explain the 
observed additive effect of zileuton on BHR, besides 
ICS, although we did not attempt to explore these possi­
bilities. It might be postulated that zileuton has, besides 
ICS, an additional inhibitory effect on the activation 
of the 5-lipoxygenase pathway. Such action would ex­
plain the increase in PD20,UNDW by an inhibitory action 
011 leukotriene (LT)C4, LTD4 and LTE4 production in­
duced by osmolar changes. Indeed, UNDW appears to 
induce leukotriene production. M eslier  et aL [30] showed 
that intranasal installation of distilled water aerosol in 
responsive subjects with allergic rhinitis raised the 
humoral and cellular content of nasal lavage fluid, in­
cluding LTB4 and LTD4, to a similar extent as after al­
lergen challenge. In contrast, there is no evidence that 
post-histamine-induced responses might be mediated 
by leukotrienes. Histamine provocation did not prov­
oke release of leukotrienes [31]. Nevertheless, it cannot 
be excluded that patients with still significant BHR des­
pite ICS are those in whom bronchoconstriction is, in 
part, dependent on leukotrienes. Another potential 
explanation is that zileuton might act, in part, as an 
antihistamine. This could explain the effects on hista­
mine reactivity as well as a smaller effect on UNDW, 
However, to our knowledge pharmacological data to 
support this concept are not available. Clearly, sub­
sequent studies are required to explore the above-men- 
tioned possibilities.
EFFECTS OF ZILEUTON ON BHR IN ICS-TREATED ASTHMATICS 2753
Finally, a potential order effect associated with tachy­
phylaxis should be considered. In this study, measure­
ments were performed with an interval of at least 5 days. 
This study design was chosen since it is known that 
histamine provocation may induce a significant bron­
choconstriction response to UNDW [17]. Tachyphylaxis 
for repeated histamine provocations may exist, as does 
refractoriness for UNDW, which may persist up to 4 h 
[17]. The half-life of zileuton is 2.5 h, and its effect on 
5-lipoxygenase activity should have been dissipated less 
than 16 h postingestion [11]. Looking at table 3, how­
ever, no order effect appeared to be present.
In conclusion, although the number of patients stud­
ied was small, the present data show that a single dose 
of 400 mg zileuton may attenuate bronchial hyperre­
sponsiveness in stero id-depen dent asthmatics. Additional 
studies are necessary to investigate whether similar effects 
are found after prolonged periods of treatment with 
zileuton.
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